MXPA03007413A - Composicion y metodo para tratar enfermedades inflamatorias. - Google Patents

Composicion y metodo para tratar enfermedades inflamatorias.

Info

Publication number: MXPA03007413A
Authority: MX; Mexico
Prior art keywords: inflammatory disorders; treating inflammatory; composition; inhibitors; antibodies
Prior art date: 2001-02-23

Application number

MXPA03007413A

Other languages

English (en)

Inventor

Kenneth Jacobs

Original Assignee

Inst Genetics Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-02-23

Filing date

2002-02-25

Publication date

2003-11-18

2002-02-25 Application filed by Inst Genetics Llc filed Critical Inst Genetics Llc

2003-11-18 Publication of MXPA03007413A publication Critical patent/MXPA03007413A/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Diabetes (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Hematology (AREA)
Obesity (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Communicable Diseases (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)

MXPA03007413A 2001-02-23 2002-02-25 Composicion y metodo para tratar enfermedades inflamatorias. MXPA03007413A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US27082301P	2001-02-23	2001-02-23
US28135301P	2001-04-03	2001-04-03
PCT/US2002/005684 WO2002068476A2 (en)	2001-02-23	2002-02-25	Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders

Publications (1)

Publication Number	Publication Date
MXPA03007413A true MXPA03007413A (es)	2003-11-18

Family

ID=26954516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MXPA03007413A MXPA03007413A (es)	2001-02-23	2002-02-25	Composicion y metodo para tratar enfermedades inflamatorias.

Country Status (9)

Country	Link
EP (1)	EP1373319A2 (es)
JP (2)	JP2005510451A (es)
AU (2)	AU2002252097A2 (es)
BR (1)	BR0207528A (es)
CA (1)	CA2438238A1 (es)
MX (1)	MXPA03007413A (es)
NZ (1)	NZ527396A (es)
WO (1)	WO2002068476A2 (es)
ZA (1)	ZA200306071B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030170823A1 (en)	1999-12-23	2003-09-11	Presnell Scott R.	Novel cytokine ZCYTO18
US7045498B2 (en)	2000-08-08	2006-05-16	Zymogenetics, Inc.	Soluble Zcytor11 cytokine receptors
US7638604B2 (en)	2001-02-23	2009-12-29	Genetics Institute, Llc	Monoclonal antibodies against interleukin-22
BR0207528A (pt) *	2001-02-23	2006-01-17	Inst Genetics Llc	Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo
WO2003083062A2 (en)	2002-03-22	2003-10-09	Zymogenetics, Inc.	Anti-il-tif antibodies and methods of using in inflammation
WO2004085475A2 (en)	2003-03-24	2004-10-07	Zymogenetics, Inc.	Anti-il-20 antibodies and binding partners and methods of using in inflammation
CA2530386A1 (en) *	2003-06-23	2005-01-06	Jing Li	Antibodies against interleukin-22 and uses therefor
US7537761B2 (en)	2004-10-22	2009-05-26	Zymogenetics, Inc.	Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
WO2006086396A2 (en)	2005-02-08	2006-08-17	Zymogenetics, Inc.	Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
KR101453570B1 (ko) *	2005-12-02	2014-10-22	제넨테크, 인크.	Ｉｌ-22 및 ｉｌ-22ｒ에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en)	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
KR102426481B1 (ko)	2013-03-15	2022-07-27	제넨테크, 인크.	IL-22 폴리펩티드 및 IL-22 Fc 융합 단백질 및 사용 방법
SG11202012014UA (en) *	2018-06-05	2021-01-28	Bioatla Inc	Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof
WO2023110942A1 (en) *	2021-12-14	2023-06-22	Charité-Universitätsmedizin Berlin	Prevention of impaired fracture healing

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030003545A1 (en) *	1998-05-29	2003-01-02	Reinhard Ebner	Interleukins-21 and 22
AU760224B2 (en) *	1998-10-26	2003-05-08	Wyeth	Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
JP4828703B2 (ja) *	1999-04-28	2011-11-30	ジェネティックスインスティテュートエルエルシー	ヒトｇｉｌ−１９／ａｅ２８９タンパク質、及び、同タンパク質をコードするポリヌクレオチド
EP1242600B1 (en) *	1999-12-23	2010-03-03	ZymoGenetics, Inc.	Cytokine zcyto18
BR0207528A (pt) *	2001-02-23	2006-01-17	Inst Genetics Llc	Anticorpo, composição farmacêutica, e, usos de uma quantidade efetiva de um agente, de uma quantidade terapeuticamente efetiva de um anticorpo para il-22, de uma quantidade imunogênica do antìgeno e uma quantidade aumentadora de imunogenicidade de il-22 em combinação, de uma quantidade efetiva do anticorpo ou fragmento do mesmo e de uma quantidade suficiente de anticorpo ou fragmento ligado a antìgeno do mesmo

2002
- 2002-02-25 BR BR0207528-8A patent/BR0207528A/pt active Search and Examination
- 2002-02-25 JP JP2002567986A patent/JP2005510451A/ja active Pending
- 2002-02-25 NZ NZ527396A patent/NZ527396A/en not_active IP Right Cessation
- 2002-02-25 MX MXPA03007413A patent/MXPA03007413A/es active IP Right Grant
- 2002-02-25 EP EP02721152A patent/EP1373319A2/en not_active Withdrawn
- 2002-02-25 WO PCT/US2002/005684 patent/WO2002068476A2/en active Application Filing
- 2002-02-25 AU AU2002252097A patent/AU2002252097A2/en not_active Abandoned
- 2002-02-25 CA CA002438238A patent/CA2438238A1/en not_active Abandoned
2003
- 2003-08-06 ZA ZA2003/06071A patent/ZA200306071B/en unknown
2008
- 2008-07-25 AU AU2008203342A patent/AU2008203342B8/en not_active Ceased
2009
- 2009-01-07 JP JP2009001211A patent/JP2009137986A/ja active Pending

Also Published As

Publication number	Publication date
AU2008203342B8 (en)	2011-03-17
EP1373319A2 (en)	2004-01-02
AU2002252097A2 (en)	2002-09-12
BR0207528A (pt)	2006-01-17
JP2005510451A (ja)	2005-04-21
WO2002068476A3 (en)	2003-08-07
JP2009137986A (ja)	2009-06-25
AU2008203342A1 (en)	2008-08-14
WO2002068476A2 (en)	2002-09-06
CA2438238A1 (en)	2002-09-06
ZA200306071B (en)	2005-11-30
NZ527396A (en)	2007-12-21
AU2008203342B2 (en)	2011-02-17

Publication	Publication Date	Title
HUS2100051I1 (hu)	2021-12-28	Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
EP1485381B8 (en)	2010-05-12	Azolylaminoazine as inhibitors of protein kinases
WO2005016962A3 (en)	2005-09-15	Compositions and methods for the treatment of immune related diseases
MXPA05005223A (es)	2010-09-07	Diaminotriazoles utiles como inhibidores de proteinas cinasas.
AU2003220299A1 (en)	2003-09-29	Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en)	2003-09-29	Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en)	2003-09-29	Compositions useful as inhibitors of protein kinases
ATE451376T1 (de)	2009-12-15	Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
IS6950A (is)	2003-09-12	Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma
TW200514776A (en)	2005-05-01	Aminotriazole compounds useful as inhibitors of protein kinases
MXPA03007413A (es)	2003-11-18	Composicion y metodo para tratar enfermedades inflamatorias.
PL1682530T3 (pl)	2007-09-28	Podstawione pirolo-indole jako inhibitory PAI-1
MXPA06014510A (es)	2007-09-19	Composiciones y metodos para tratar trastornos inflamatorios.
ATE358485T1 (de)	2007-04-15	Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
IL209338A0 (en)	2011-01-31	Pharmaceutical compositions containing anti-cd-3 antibodies
WO2003010291A3 (en)	2004-02-19	Treatment of immune disorders and b cell disorders
TW200505443A (en)	2005-02-16	Combination of SCR kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases
TW200508233A (en)	2005-03-01	Chk-1 inhibitors
DE60329326D1 (de)	2009-10-29	Tace inhibitoren
ATE335739T1 (de)	2006-09-15	Cak inhibitoren und deren verwendungen
AU2002326745A1 (en)	2003-03-10	Compositions and methods for generating antigen-binding units
IL154522A0 (en)	2003-09-17	IgE RECEPTOR ANTAGONISTS
ZA200610474B (en)	2009-09-30	Compositions and methods for treating inflammatory disorders
MXPA05009428A (es)	2005-12-12	Composiciones y metodos para prevenir y tratar enfermedades relacionadas con endotoxinas.
DE60325737D1 (de)	2009-02-26	Verfahren und zusammensetzungen zum targeting sekretorischer lysosomen

Legal Events

Date	Code	Title	Description
2010-09-14	FG	Grant or registration